Zacks Investment Research Downgrades Celsion (CLSN) to Hold
Celsion (NASDAQ:CLSN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
Separately, ValuEngine upgraded shares of Celsion from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.
Celsion (NASDAQ:CLSN) last posted its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.19). Celsion had a negative net margin of 4,479.42% and a negative return on equity of 109.99%. The company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, analysts anticipate that Celsion will post -1.17 EPS for the current year.
An institutional investor recently raised its position in Celsion stock. BlackRock Inc. raised its stake in shares of Celsion Co. (NASDAQ:CLSN) by 72.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,844 shares of the biotechnology company’s stock after acquiring an additional 48,194 shares during the quarter. BlackRock Inc. owned approximately 0.65% of Celsion worth $339,000 at the end of the most recent quarter. 4.83% of the stock is owned by institutional investors and hedge funds.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.
See Also: Buyback
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.